Promoted Content Promoted Content

X

Find FDA Investigational New Drug (IND) Submissions for Cardiology/Vascular Diseases in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VERVE-101

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: VERVE-101

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 11, 2021

            Details:

            Disease model of HeFH, the company’s mouse surrogate version of VERVE-101 produced similar and robust amounts of PCSK9 editing in the liver, above 50%, at doses of 0.05, 0.1 and 0.5 mg/kg administered as a single dose to wild-type and heterozygous LDLR knockout mice.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AAV-gene therapy

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: RTW Investments

            Deal Size: $106.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing March 01, 2021

            Details:

            The new funding will allow Tenaya to advance its lead gene therapy program towards clinical studies; progress new programs towards IND-enabling studies; build on existing drug discovery and development capabilities across its three platform.